Phase II study of Iressa with/without concurrent chemoradiotherapy in patients with advanced non-nasopharyngeal head and neck carcinoma and to study the effect of Iressa (ZD1839) [gefitinib] on tumour gene expression profiles
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2007
At a glance
- Drugs Gefitinib (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 18 Dec 2007 Status changed from in progress to completed.
- 20 Nov 2006 Status change
- 02 Nov 2005 New trial record.